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INTRODUCTION 
Patients with Chronic kidney disease 
(CKD) have greater risk to experience 
cardiovascular events with poor outcome. Morbidity 
and mortality due to cardiovascular events increases 
associated with the reduced of GFR below 60 
ml/min/1,73m2. In patients with hemodialysis the 
prevalence of coronary heart disease reach 
approximately 40% with 9% annual mortality rate. 
Patients with history of previous acute coronary 
syndrome (ACS) have greater risk of recurrence 
attack. Adequate  secondary preventions are 
expected to increase survival in concise period of 
time and costly effective. We report a case of ACS in 
a patient with CKD stage V due to diabetic 
nephropathy who has undergone routine 
hemodialysis
CASE PRESENTATION : a 58 years old male 
Javanese patient with CKD stage V due to diabetic 
nephropathy presented to our  emergency unit with 
squeezed-like, heavy chest pain  radiating to the 
back, without nausea and vomiting, 6 hours previous 
to  admission. The pain was experienced in about 
one hour and it was not resolved by rest. He has 
undergone routine haemodyalisis once a week since 
the last past year. He also suffered from diabetes 
mellitus and poorly-controlled hypertension since 
the past 5 years.
Physical examinations revealed the patient 
was compos mentis, blood pressure 170/100 mmHg, 
heart rate 98x/minute, respiration rate was 
20x/minute. The patient's conjunctiva was pale, JVP 
5+3 cm H2O, cardiomegaly was found, S1 and S2 
regular, murmur was negative. Moist basal rales was 
also found in both fields of lungs. There were no 
signs of hepatomegaly nor edema of the extremities.
Laboratory findings : Hb 9.4 g/dl, WBC 
3 3 3 311.7 x 10 /mm , PLT 187x10 /mm , MCV 84.4 %, 
MCH 29.6 %. Albumin 2.83 g/dl, BUN 73.2 mg/dl, 
creatinine 14.18 mg/dl, clearance creatinine test 
(CCT)  5.1, uric acid 6.4 mg/dl. Kalium (K) 5.5 
mEq/. SGOT 19 IU, CK 197 IU/L, CKMB 3.1 U/L, 
Troponin I 0.33. ECG was sinus rhythm, 98/minute, 
Left ventricular hypertrophy (LVH), depressed ST 
segment in precordial leads V4 - V6. Urinalysis was 
as follow : glucose +1, proteinuria +4, protein 
Esbach 9 gram. Blood lipid profiles showed total 
cholesterol 225 mg/dl, trigliseride 159 mg/dl, HDL 
42 mg/dl, LDL 149 mg/dl. HbA1C level was 7,4%, 
fasting plasma glucose was 111 mg/dl, and 2 hours 
post prandial plasma glucose was 139 mg/dl. There 
were no significant difference in serial cardiac 
enzyme and ECG evaluation. Troponin I 0.41, 
CKMB 4.6 U/L, SGOT 18 IU/L, and LDH 477 IU/L.
After therapy with O2 3L/minute, 
administration of 2 mg i.v. morphine injection, 
sublingual ISDN 5 mg, and aspilet 320 mg in the 
E.R., symptom of chest pain diminished. Then,  the 
patient was admitted to ICCU and treated therapies 
as follows : O2 3L/menit, IVFD of NaCl 0,9 % 
micro-line, administration of unfractionated 
heparin for 3 days, aspilet 80 once a day, ISDN 5 mg 
three times a day, adalat oros 30 mg once a day, 
valsartan 80 mg once a day, CaCO3 1 tab three times 
a day, and folic acid 1 tab three times a day. 
Haemodyalisis was performed twice and one bagf 
redo-blood cell transfusion was also given. The 
patient condition was gradually resolved during 
treatment, chest pain was diminished, and the basal 
moist rhales in both fields of lungs started to fade 
away. After the patient pulmonary edema was 
reduced, the patient was managed with additional 
therapy, bisoprolol 2,5 mg once a day. He was 
discharged on day 6 after early mobilization in the 
ward.
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Figure 1. ECG at  E.R
sinus rhythm, 98/minute, LVH, 
depressed ST segment in 
precordial leads V4 - V6
Figure 2. ECG at ICCU.
sinus rhythm, 98/minute, LVH, depressed ST segment in precordial 
leads V4 - V6
DISCUSSION
Cardiac and renal diseases are common and 
frequently coexist. The interaction between both of 
them is well known as cardio-renal syndrome 
(CRS), whereby acute or chronic dysfunction of 1 
organ may induce acute or chronic dysfunction of 
the other. In the fourth subtype of CRS, CKD 
induces cardiac disease including chronic heart 
disease (LV remodelling and disfunction, diastolic 
dysfunction, abnormalitis in cardiac function), acute 
1heart failure, and ACS . Internal milleu in CKD 
patients support the development of CAD. A number 
of traditional and non-traditional risk factors of 
CAD were found in patients with CKD, i.e. elderly, 
diabetes melliltus, hipertension, dyslipdemia, LVH, 
s y s t e m i c  i n f l a m m a t i o n ,  p r o t e i n u r i a ,  
hyperhomocysteinemia, imbalance of phosphor and 
calcium, increment of Asymmetric dimethyl 
2arginine (ADMA) .
Secondary preventions are defined as the 
managements taken to prevent reccurent 
cardiovascular event and to decline the 
cardiovascular morbidity in patients with vascular 
3atherosclerosis . Some measurements and therapies 
has been proven to be effectively reduce the ACS 
reccurence risks. i.e. :
1.Life style modification
Life style modification includes cessation 
of smoking, sports, and reduced-body weight. 
Cessation of smoking is the first and the most 
ultimate step. Nicotine therapy, bupropione and 
antidepressant might be of benefit in efforts to stop 
the smoking habit. Recommended sports are aerobic 
sports for about 30 minutes daily or at least 5 times a 
week. Body weight loss efforts are aimed to  achieve 
Body Mass Index (BMI) < 25 kg/m2 or waist 
circumference < 102 cm for men and < 88 cm for 
women
2. Blood pressure control
Target of blood pressure control is less than 
140/90 mmHg ini non diabetic patients and less than 
130/80 mmHg in diabetic patients or chronic renal 
impairment. Meanwhile, the target of blood pressure 
in CKD patients with proteinuria more than 1 g/day 
4,5is less than 125/75 mmHg . 
Hypertension management in CKD patients 
includes the management of fluid balance, lows 
odium diet and anti hypertension agents. Anti 
hypertension drugs of choice in patients with CKD 
are ACE inhibitor dan ARB. ACE inhibitors and 
ARBs can improve the glomerular membrane 
permeability and reduce proteinuria, and also 
2,5decline the ADMA levels . 
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Table 2. Dose adjustification of drug lowering lipid
Statin agent
 
GFR 60-90 
ml/min/1,73 m2
 GFR 15-59 
ml/min/1,73 m2
 GFR <15 
ml/min/1,73 m2
 notes
 
Atorvastatin
 
No
 
No
  
No
    
dose to one-half at GFR 
<30 ml/min/1,73 m2
 
Fluvastatin
 
No
 
Not defined
 
Not defined
    
dose to one-half at GFR 
<30 ml/min/1,73 m2
 
Lovastatin
 
No
     
to 50%
     
to 50%
 
Start 10 mg a day for 
GFR <60 ml/min/1,73 m2
Pravastatin No No No  Start 5 mg a day for  GFR 
<30 ml/min/1,73 m2 max 
dose 10 mg/day  
Rosuvastatin No 5-10 mg 5-10 mg  Start at 5 mg/day if GFR 
<10 ml/min/1,73 m2  
Simvastatin  No No 5 mg   
Non statin     
Nicotinic 
acid 
No No     to 50%  34% kidney excretion  
Cholestyrami
ne 
No No  No  Not absorbed  
Colesevelarn No No No  Not absorbed  
Ezetimibe No No No   Fenofibrate     to 50%    to 25% Avoid  May   serum creatinin  Gemfibrozil
 
No
 
No
 
No
 
NLA recommends a dose 
of 600 mg/day for GFR 
15-59 ml/mim/1,73 m2
 and avoiding for GFR
 <15 ml/mim/1,73 m2
 Omega-3 Fas No No No
       = decrease      = increase FA = fatty acid GFR = glomerular filtration rate NLA = national lipid foundation
(Source :Harper et al, 2008)
During treatment, the patient was 
treated with simvastatin  20 mg once a day. 
Patient GFR was less than 15 ml/menit/1,73 
m2, simvastatin should be given with dosage of 
5 mg daily or managed with other type of statins 
that do not require dose adjusment such as 
atorvastatin atau fluvastatin.
5. Angiotensin converting enzyme inhibitor and 
angiotensin receptor blocker
 ACE inhibitor with proven efficacy in 
secondary prevention of ACS are ramipril and 
perindropril . ACE inhibitor should be given 
from low dosage and up-titrated every 2 weeks 
until maximum dose or well-tolerated dose is 
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achieved. ACE inhibitor dan ARBs utilization 
should be discontinued if there is an increment 
of creatinine more than 35 % from baseline or 
 2hyperkalemia .
  Angiotensin receptor blocker can be 
used for replacement of ACE inhibitor when 
contraindications presents or be used in 
combination. Combination theerapy is 
especially aimed for patients with proteinuria 
more than 1g/day with monitoring of increased 
risk of hyperkalemia. Although the efficacy is 
similar, ACE inhibitor is more recommended 
8for patients with heart failure .
In regards to patients with comorbidity 
of congestive heart failure, ACE inhibitors such 
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as ramipril should be prefered. Although 
proteinuria 9 gr/24 hours is present, ACE 
inhibitor administration is better not  be 
combined with ARBs. This patient underwent 
hemodialysis once a week, thus he has risk of 
hyperkalemia if ACE inhibitor and ARB is 
administered in combination. 
6. â blocker
Long-term oral â blocker treatment is 
recommended for all patients with ACS with or 
without left ventricle function impairment as 
7long as there is no contraindication . â blocker 
usage is also recommended for patients with 
5CKD . At present, â blocker types that has been 
proven for their efficacy in secondary 
prevention of AMI are propanolol, timolol, 
metoprolol, and carvedilol. For unstable angina 
pectoris secondary prevention, it has not been 
established yet which â blocker has better 
efficacy. â blockers recommended for patients 
with heart failure comorbidity are carvedilol, 
8metoprolol, and bisoprolol .
The patient had already been treated 
with bisoprolol, a â blocker, as one of his anti-
hypertension therapy and also for the anti-
ischemic agent.
7. Antiplatelet agents
In this case, the patient received 80 mg 
aspirin once a day as an antiplatelet. 
Antiplatelet of choices to prevent ACS are 
aspirin and or Thienopyridine (clopidogrel and 
ticlopidin). A combination of aspirin and 
clopidogrel has been proved superior to aspirin 
in reducing cardiovascular mortality, ACS 
reccurency and strokes. The combination of 
aspirin and clopidogrel was administered for 12 
7months in this patient with ACS . 
8. Influenza vaccination         .
Patients with chronic cardiovascular disease 
have a greater risk for experiencing 
complications from influenza. Influenza can 
lead to exacerbation of underlying medical 
disorders such as diabetes mellitus and 
cardiovascular disease, leading to viral 
pneumonia, secondary bacterial pneumonia, as 
well as coinfection with other viruses and 
bacteria. The inflammatory response of our 
body to viral infections could be expected to 
lead the formation of auto-antibody which 
causes changes in LDL. It will lead to the 
development and progression of vascular 
atheroslerosis. Therefore, the AHA / ACC 
recommends annual influenza vaccine in this 
group of patients with CHD or other 
atherosclerotic vascular disease. Types of 
influenza vaccines that are allowed to be given 
9is the inactive form . Infuenza vaccine has not 
been given as secondary prevention in these 
patients. This is due to the unavailable vaccine 
in Dr.Sardjito Hospital and cost constraints.
CONCLUSION
In conclusion, this case supports the 
secondary prevention of ACS in patient with 
CKD. 
Education plays an important role to increase 
patients compliance for this life long treatment 
time duration. Aside from influenza 
vaccination, all of the ACS secondary 
preventions has been given to this patient. 
Based on medical record, no cardiovascular 
events were recorded until this paper was 
written.
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S U B J E C T I N D E X
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